Akorn, Inc. (NASDAQ:AKRX) has earned a consensus rating of “Hold” from the fifteen analysts that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $28.56.

A number of research firms have recently commented on AKRX. TheStreet upgraded Akorn from a “c+” rating to a “b-” rating in a research report on Thursday, April 20th. Royal Bank Of Canada set a $34.00 target price on Akorn and gave the company a “hold” rating in a research report on Saturday, May 27th. William Blair downgraded Akorn from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 25th. Piper Jaffray Companies reiterated a “hold” rating and set a $34.00 target price on shares of Akorn in a research report on Thursday. Finally, Jefferies Group LLC downgraded Akorn from a “buy” rating to a “hold” rating and increased their target price for the company from $24.00 to $34.00 in a research report on Tuesday, April 25th.

Shares of Akorn (AKRX) traded down 0.03% during midday trading on Friday, hitting $33.31. 1,781,794 shares of the stock were exchanged. The firm has a market cap of $4.16 billion, a PE ratio of 33.65 and a beta of 1.36. The firm’s 50-day moving average is $33.54 and its 200 day moving average is $29.05. Akorn has a 52-week low of $17.61 and a 52-week high of $34.00.

TRADEMARK VIOLATION NOTICE: “Akorn, Inc. (AKRX) Given Average Recommendation of “Hold” by Brokerages” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/akorn-inc-akrx-given-average-recommendation-of-hold-by-brokerages/1476207.html.

In related news, COO Bruce Kutinsky sold 40,000 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $33.46, for a total value of $1,338,400.00. Following the completion of the sale, the chief operating officer now directly owns 317,480 shares in the company, valued at $10,622,880.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Brian Tambi sold 5,165 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $33.37, for a total value of $172,356.05. The disclosure for this sale can be found here. 28.20% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of AKRX. State Treasurer State of Michigan increased its stake in Akorn by 0.3% in the first quarter. State Treasurer State of Michigan now owns 35,400 shares of the company’s stock valued at $852,000 after buying an additional 100 shares during the period. Public Employees Retirement Association of Colorado increased its stake in Akorn by 0.8% in the second quarter. Public Employees Retirement Association of Colorado now owns 19,534 shares of the company’s stock valued at $655,000 after buying an additional 158 shares during the period. Pacer Advisors Inc. increased its stake in Akorn by 1.4% in the second quarter. Pacer Advisors Inc. now owns 12,889 shares of the company’s stock valued at $432,000 after buying an additional 180 shares during the period. Mason Street Advisors LLC increased its stake in Akorn by 0.6% in the first quarter. Mason Street Advisors LLC now owns 41,143 shares of the company’s stock valued at $991,000 after buying an additional 226 shares during the period. Finally, Advantus Capital Management Inc increased its stake in Akorn by 2.3% in the first quarter. Advantus Capital Management Inc now owns 11,151 shares of the company’s stock valued at $269,000 after buying an additional 256 shares during the period. Institutional investors own 74.73% of the company’s stock.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Analyst Recommendations for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.